Showing 4011-4020 of 6038 results for "".
- Industry Optimism Surges: Three Ways for Dermatologists to Capitalizehttps://practicaldermatology.com/news/industry-optimism-surges-three-way-for-dermatologists-to-capitalize/2460745/Despite a tumultuous past year, a recent Medscape survey shows that 85 percent of dermatologists are happy with their profession and optimistic about the future. This optimism is likely brought on by
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid
- Dr. Adam Friedman Named Chair of Dermatology at George Washington Universityhttps://practicaldermatology.com/news/dr-adam-friedman-named-chair-of-dermatology-at-george-washington-university/2460718/Adam Friedman, MD has been
- Industry Responds to COVID-19: Janssen Pharmaceutical Companieshttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat-janssen-pharmaceutical-companies/2460694/In response to the COVID-19 pandemic, Janssen Pharmaceutical Companies of Johnson & Johnson, “has been collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existi
- Almirall, MC2 Therapeutics Strike Deal to Distribute Wynzora in Europehttps://practicaldermatology.com/news/almirall-mc2-therapeutics-strike-deal-to-distribute-wynzora-in-europe/2460692/
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end
- IPC Weighs In On COVID-19 Vaccine Safety and Psoriasishttps://practicaldermatology.com/news/ipc-weighs-in-on-covid-19-vaccine-safety-and-psoriasis/2460623/The International Psoriasis Council (IPC) released guidance on the potential impact of psoriasis therapy, particularly systemic therapy, on a SARS-CoV-2 vaccine. The principal considerations for SARS-CoV-2 vaccines are the same as for any vaccine, the IPC notes. Avo
- UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, Other Diseaseshttps://practicaldermatology.com/news/ucb-stanford-medical-partner-to-seek-new-ways-to-treat-hs-other-diseases/2460613/UCB and